ClinicalTrials.gg
Enrolling by invitationNCT06883084Updated Mar 19, 2025

Clinical Relevance of Pathologic Regression IN Lymph Node for Locally Advanced Rectal Cancer

An observational study in Rectal Cancer and Lymph Node Metastasis, sponsored by Yanhong Deng. Enrolling by invitation. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-03-19.

Sponsored by Yanhong Deng · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,080
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Rectal Neoplasms by Yanhong Deng — 4 open to participants now, 4 under way, 1 of them phase 3. Rectal Neoplasms · Yanhong Deng.

Started
2014
the only one that year
Observational
7 of 11
2 open now
Registered
9th of 11
by date

Among the 11 studies in Rectal Neoplasms by Yanhong Deng, this one is the only one that started in 2014, is one of 7 observational ones, and was the 9th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

4 of the 11 studies in Rectal Neoplasms by Yanhong Deng are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Rectal Neoplasms by Yanhong Deng, or all of them as a file.
02

Study summary

We evaluated all related clinical and pathologic data of patients with Locally Advanced Rectal Cancer following Neoadjuvant Chemoradiotherapy, including the pathologic regression grading in the primary tumor site and lymph node, and other histopathologic characteristics. Finally, the present study was aimed at (1) clarifying the clinical significance of the Major Pathologic Regression for Locally Advanced Rectal Cancer following Locally Advanced Rectal Cancer in the primary tumor site and lymph node, and (2) comparing different Neoadjuvant Chemoradiotherapy treatments of this uncommon disease through conducting a large, multi-center cohort study.

Read the detailed description

This large-scale, multi-center cohort study investigates the clinical significance of Pathologic Regression in lymph nodes (LNs) of patients with Locally Advanced Rectal Cancer (LARC) following Neoadjuvant Chemoradiotherapy (NCRT). Additionally, it compares the efficacy of diverse NCRT regimens in achieving pathologic regression and improving survival outcomes.

Study Design Type: Retrospective and prospective observational cohort study. Setting: Multi-center collaboration across 14 academic and community hospitals. Timeframe: Data from patients treated between 2014 and 2025 will be analyzed, with prospective follow-up ongoing until 2026.

Primary Objectives

Clarify the clinical significance of tumor regression in LN:

Define MPR thresholds for both primary tumor (e.g., ≤10% residual viable tumor) and lymph nodes (e.g., complete LN regression [ypN-Reg+] versus residual LN disease [ypN+]).

Correlate MPR status in the primary tumor and LNs with long-term outcomes:

Primary endpoints: Progression-Free Survival (PFS), Overall Survival (OS). Secondary endpoints: Local recurrence rate, distant metastasis-free survival.

Compare NCRT regimens:

Evaluate differences in MPR rates and survival outcomes between fluoropyrimidine-based, oxaliplatin-containing, and immunotherapy-augmented NCRT protocols.

Assess the impact of radiation dose escalation (e.g., 50.4 Gy vs. 45 Gy) on pathologic regression.

Study Population

Inclusion Criteria:

Adults (≥18 years) with histologically confirmed LARC (clinical stage II-III). Completion of NCRT followed by total mesorectal excision (TME). Availability of standardized pathologic reports and digitized whole-slide images (WSIs) for both primary tumor and LNs.

Exclusion Criteria:

Metastatic disease at diagnosis. Incomplete NCRT or surgical resection. Data Collection

Clinical Variables:

Demographics, NCRT regimen (drugs, doses, duration), surgical complications, adjuvant therapy, recurrence patterns.

Pathologic Variables:

Primary tumor: Residual viable tumor percentage, necrosis extent, tumor-infiltrating lymphocyte (TLS) density.

Lymph nodes: Regression grading (ypN-Reg+/-), number of regressed vs. metastatic LNs.

AI-driven quantitative analysis: Necrosis-to-tumor ratio (NECR-TD), TLS-to-necrosis ratio (T/NR), and spatial distribution of regressive features (Figure S2).

Imaging and Biomarkers:

Pre-treatment MRI-based tumor staging, post-treatment radiomic features (if available).

Statistical Analysis

Survival Analysis:

Kaplan-Meier curves and multivariable Cox regression to identify predictors of DFS/OS, adjusting for age, stage, and treatment regimen.

Subgroup analysis of LN regression (ypN-Reg+ vs. ypN-Reg-) in patients with ypN0 status.

Comparative Effectiveness:

Propensity score matching to balance baseline characteristics across NCRT regimens.

Meta-analysis of pooled multi-center data to assess heterogeneity in treatment effects.

Machine Learning:

Develop prognostic models integrating MPR status, histopathologic parameters, and clinical variables.

Ethical Considerations Approved by the Institutional Review Boards (IRBs) of all participating centers Innovation and Impact

Dual Focus on Primary Tumor and LNs:

First study to evaluate MPR thresholds simultaneously in primary tumor and LNs, addressing their independent prognostic roles.

Translational Insights:

Link LN regression to systemic immune responses (e.g., abscopal effect) and molecular heterogeneity between primary and metastatic sites.

Clinical Utility:

Provide evidence for standardizing MPR definitions in LARC and optimizing NCRT regimens based on tumor biology.

03

Conditions studied

  • Rectal Cancer
  • Lymph Node Metastasis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

patients with Locally Advanced Rectal Cancer following Locally Advanced Rectal Cancer

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (≥18 years) diagnosed with locally advanced rectal adenocarcinoma (clinical stage II-III).

Completion of NCRT followed by curative-intent surgery. Availability of pre- and post-treatment histopathologic data, including standardized regression grading and digitized whole-slide images (WSIs).

Exclusion criteria

Exclusion Criteria:

  • distant disease at diagnosis. Incomplete clinical or pathologic records.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,080 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. PFS

    Progression free survival

    Time frame: 10 years

  2. OS

    Overall survival

    Time frame: 10 years

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2014 (actual). Primary completion is estimated for Dec 2025, 143 months after the start.

Of 214 non-industry observational studies under Rectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 118. This study's planned 143 months is above that.

Counting every sponsor, half of 229 studies reached it within 45 months; a quarter within 24 and three quarters within 116.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2025
First posted
Mar 19, 2025
StartActual
Jan 30, 2014
Primary completionEst.
Dec 30, 2025
CompletionEst.
Feb 25, 2026
Last update
Mar 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06883084
Lead sponsor
Yanhong Deng
Responsible party
Yanhong Deng (M.D., Sun Yat-sen University) — Sponsor-investigator
First posted
Mar 19, 2025
Start date
Jan 30, 2014
Primary completion
Dec 30, 2025 (estimated)
Completion
Feb 25, 2026 (estimated)
Last update
Mar 19, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion